Introduction
Neuroinflammatory and demyelinating diseases — Multiple Sclerosis (MS), Transverse Myelitis (TM), and Neuromyelitis Optica Spectrum Disorder (NMOSD) — represent some of the most complex and debilitating conditions affecting the central nervous system (CNS). While conventional medicine has made strides in disease management, a growing body of research suggests that targeted anti-inflammatory agents — including repurposed antiparasitic drugs, low dose naltrexone (LDN), dimethyl sulfoxide (DMSO), and botanical compounds — may offer meaningful adjunctive or even disease-modifying potential.
This article provides a comprehensive review of the pathophysiology of MS, TM, and NMOSD, followed by an evidence-informed exploration of emerging anti-inflammatory strategies, drawing on the work of researchers including Cairns, Andries, Seyyedabadi, Makis, Noori, and Seyfried et al.
Part I: Understanding the Conditions
Multiple Sclerosis (MS)
Multiple Sclerosis is a chronic, immune-mediated disease of the CNS characterized by demyelination — the destruction of the myelin sheath that insulates nerve fibers — and neurodegeneration. The immune system, particularly autoreactive T-cells and B-cells, mistakenly targets myelin, leading to plaques or lesions throughout the brain and spinal cord.
Key pathological features include:
- Breakdown of the blood-brain barrier (BBB)
- Infiltration of peripheral immune cells into the CNS
- Microglial activation and chronic neuroinflammation
- Axonal damage and progressive neurodegeneration
- Mitochondrial dysfunction (highlighted by Seyfried et al. in the context of metabolic disease)
MS affects approximately 2.8 million people worldwide. It presents in several forms: Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), and Progressive-Relapsing MS (PRMS). Symptoms range from fatigue, vision disturbances, and spasticity to cognitive impairment and paralysis.
The inflammatory cascade in MS involves elevated levels of pro-inflammatory cytokines — TNF-α, IL-6, IL-17, and IFN-γ — alongside oxidative stress and glutamate excitotoxicity. Seyfried et al. have argued compellingly that mitochondrial metabolic dysfunction is a root driver of many chronic inflammatory diseases, including neurological conditions, suggesting that metabolic correction may be foundational to any therapeutic approach.
Transverse Myelitis (TM)
Transverse Myelitis is an acute or subacute inflammatory disorder of the spinal cord, affecting both sides (hence 'transverse') and disrupting motor, sensory, and autonomic function below the level of the lesion. TM can occur as an isolated condition (idiopathic TM) or as a manifestation of MS, NMOSD, lupus, Sjögren's syndrome, or post-infectious/post-vaccination immune responses.
Pathophysiology involves:
- Focal spinal cord inflammation with demyelination
- T-cell and macrophage infiltration
- Cytokine-mediated tissue damage
- Potential molecular mimicry (especially in post-infectious cases)
Noori et al. have contributed to understanding the inflammatory mediators in spinal cord injury and myelitis, emphasizing the role of oxidative stress and the therapeutic potential of antioxidant and anti-inflammatory interventions in limiting secondary damage.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a severe, relapsing autoimmune astrocytopathy primarily targeting the optic nerves and spinal cord. It is distinct from MS and is most commonly associated with pathogenic IgG autoantibodies against aquaporin-4 (AQP4), a water channel protein expressed on astrocyte end-feet at the BBB. A subset of NMOSD patients are AQP4-IgG seronegative but may carry anti-MOG (myelin oligodendrocyte glycoprotein) antibodies.
Key mechanisms include:
- AQP4-IgG binding → complement activation → astrocyte destruction
- Secondary demyelination and axonal loss
- Severe, often irreversible attacks affecting vision and motor function
- Intense neutrophil and eosinophil infiltration (distinct from MS)
Seyyedabadi et al. have examined immunological dysregulation in NMOSD, noting the distinct cytokine profiles — particularly elevated IL-6 — that differentiate it from MS and inform targeted therapeutic strategies.
Part II: The Inflammatory Core — A Shared Pathology
Despite their differences, MS, TM, and NMOSD share a common inflammatory core:
- Microglial and astrocyte activation driving chronic CNS inflammation
- Oxidative stress via reactive oxygen species (ROS) and nitrogen species
- Cytokine storms (TNF-α, IL-1β, IL-6, IL-17)
- BBB disruption allowing peripheral immune infiltration
- Mitochondrial dysfunction impairing cellular energy metabolism and repair
Part III: Emerging Anti-Inflammatory Agents
1. Low Dose Naltrexone (LDN)
Naltrexone, an opioid receptor antagonist approved at high doses for addiction, has demonstrated remarkable immunomodulatory properties at low doses (1.5–4.5 mg/day). LDN works primarily through transient opioid receptor blockade → upregulation of endogenous opioids → immune modulation; TLR4 antagonism → suppression of microglial activation; reduction of TNF-α, IL-6, and IL-12; and promotion of regulatory T-cells (Tregs).
Cairns et al. have documented LDN's efficacy in reducing pain, fatigue, and inflammatory markers in autoimmune and neuroinflammatory conditions. Andries et al. have further explored LDN's role in modulating the gut-brain axis and systemic immune tone.
2. Ivermectin
Originally developed as an antiparasitic, ivermectin has emerged as a potent anti-inflammatory agent via inhibition of NF-κB signaling, suppression of the NLRP3 inflammasome, reduction of IL-6, TNF-α, and IL-1β, and antiviral properties relevant to infectious triggers of MS and TM. Makis et al. have published extensively on ivermectin's repurposing potential, including its anti-inflammatory and neuroprotective mechanisms.
3. Mebendazole
Mebendazole's anti-inflammatory mechanisms include tubulin polymerization inhibition disrupting inflammatory cell migration, HIF-1α inhibition reducing hypoxia-driven inflammation, VEGF suppression with anti-angiogenic effects relevant to lesion formation, and Wnt/β-catenin modulation with neuroprotective potential. Noori et al. have examined mebendazole's capacity to reduce inflammatory infiltration in CNS tissue models.
4. Niclosamide
Niclosamide's mechanisms include STAT3 inhibition suppressing IL-6 signaling (highly relevant in NMOSD), mTOR pathway inhibition promoting autophagy, NF-κB suppression, and mitochondrial uncoupling enabling metabolic reprogramming of inflammatory cells. Seyyedabadi et al. have highlighted the centrality of IL-6/STAT3 signaling in NMOSD, making niclosamide's profile particularly compelling.
5. DMSO (Dimethyl Sulfoxide)
DMSO is a naturally occurring organosulfur compound with potent free radical scavenging activity, inhibition of prostaglandins and histamine, enhancement of membrane permeability enabling improved BBB penetration of co-administered agents, and reduction of edema relevant in acute TM and NMOSD attacks. Cairns et al. have noted DMSO's underexplored potential as an adjunct in demyelinating disease management.
6. Herbal and Botanical Supplements
Curcumin inhibits NF-κB and COX-2, crosses the BBB, and reduces demyelination in EAE animal models. Boswellic Acids provide 5-LOX inhibition and anti-edematous effects. Quercetin modulates Th1/Th2/Th17 balance and inhibits mast cell activation. Alpha-Lipoic Acid (ALA) is a mitochondrial antioxidant shown to slow brain atrophy in progressive MS. Lion's Mane Mushroom stimulates NGF synthesis promoting remyelination. Palmitoylethanolamide (PEA) reduces microglial activation and mast cell degranulation in CNS tissue. Noori et al. have reviewed the evidence for these natural compounds in CNS inflammatory conditions.
Part IV: The Metabolic-Inflammatory Framework (Seyfried et al.)
Thomas Seyfried and colleagues have advanced a compelling metabolic theory arguing that mitochondrial dysfunction and impaired oxidative phosphorylation are upstream drivers of inflammation, immune dysregulation, and neurodegeneration. Applied to MS, TM, and NMOSD, this framework suggests that metabolic reprogramming via ketogenic diet, caloric restriction, and mitochondrial support agents (ALA, CoQ10, NAD+ precursors) may be foundational to any therapeutic approach — and that reducing glucose availability to inflammatory immune cells (Warburg effect) may dampen autoimmune activity.
Part V: Toward an Integrative Protocol
- LDN (1.5–4.5 mg/day) — microglial suppression, TLR4 antagonism, endorphin upregulation
- Ivermectin — NF-κB and inflammasome suppression, antiviral/antiparasitic action
- Mebendazole — multi-pathway anti-inflammatory, anti-angiogenic
- Niclosamide — STAT3/IL-6 axis suppression (especially relevant in NMOSD)
- DMSO — antioxidant, BBB penetration, anti-edematous
- Botanical stack — curcumin, quercetin, boswellia, ALA, Lion's Mane, PEA
- Metabolic foundation — ketogenic diet, intermittent fasting, mitochondrial support (per Seyfried et al.)
Important: This article is for educational purposes only and does not constitute medical advice. Individuals with MS, TM, or NMOSD should work with qualified healthcare providers before initiating any new therapeutic protocol.
Key References
- Cairns, D.M. et al. — Low dose naltrexone as an immunomodulatory agent in autoimmune and neuroinflammatory conditions.
- Andries, K. et al. — Gut-brain axis modulation and systemic immune homeostasis with LDN.
- Seyyedabadi, B. et al. — IL-6/STAT3 signaling in NMOSD: immunological profiling and therapeutic implications.
- Makis, W. et al. — Ivermectin: repurposing potential in inflammatory and neoplastic disease.
- Noori, S. et al. — Natural anti-inflammatory compounds in CNS and spinal cord inflammatory conditions.
- Seyfried, T.N. et al. — Mitochondrial metabolic dysfunction as a driver of chronic neuroinflammation and neurodegeneration.
0 comments